急性重复性癫痫发作市场机会、成长动力、产业趋势分析与预测 2024 - 2032

Acute Repetitive Seizures Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月16日 | 出版商:

Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球急性反覆发作市场规模达到 27 亿美元，预计 2024-2032 年复合年增长率为 12.4%。这种增长主要归因于癫痫发病率的上升和紧急治疗方案的创新。鼻内製剂的最新进展显着改变了市场格局。提供快速、非侵入性给药的新疗法越来越受欢迎，特别是在家庭护理环境中，可近性对于患者及其照护者来说至关重要。这些鼻内疗法的易用性和快速作用加速了它们的采用，允许在没有专业医疗监督的情况下立即进行干预。

急性重复性癫痫发作，也称为癫痫丛集，是指在短时间内（通常为 24 至 48 小时）内发生一系列癫痫发作时发生的情况。这些发作可能会升级为癫痫持续状态，这是一种可能危及生命的疾病。对于许多癫痫患者，尤其是那些难以控制癫痫发作的人来说，解决 ARS 至关重要。对有效治疗方案日益增长的需求正在推动市场向前发展。

在产品分类方面，市场包括一系列解决方案，每种解决方案都能满足患者的特定需求。主要细分市场之一的特点是其用户友好和非侵入性的输送方法，有利于快速吸收和快速控制癫痫发作——这是紧急情况下的一个重要因素。监管机构对某些治疗方法的批准进一步提高了它们在医疗保健界的接受度和使用。在考虑分销管道时，市场分为医院药房、零售药房和线上平台。

市场范围
开始年份	2023年
预测年份	2024-2032
起始值	27亿美元
预测值	77 亿美元
复合年增长率	12.4%

医院药房预计将显着增长，预计复合年增长率为 12.2%。这一增长是由于与急性反覆癫痫发作相关的频繁住院导致对有效癫痫治疗药物的需求增加。此外，这些药局经常与专家密切合作，制定有效的癫痫治疗方案，从而提高药物的可近性和疗效。北美急性重复性癫痫发作市场到 2023 年将达到 11 亿美元，预计将以 12.3% 的复合年增长率成长。

该地区癫痫的高盛行率极大地影响了对有效治疗方案的需求，而完善的医疗保健系统则支持及时诊断和介入。此外，大众对癫痫的认识和教育的提高导致诊断更加频繁，进一步推动市场成长。总体而言，随着对有效、可及的治疗方案的需求不断增加，急性反覆癫痫发作市场有望取得重大进展。

The Global Acute Repetitive Seizures Market reached USD 2.7 billion in 2023 and is projected to experience 12.4% CAGR over 2024-2032. This growth is primarily attributed to the rising incidence of epilepsy and innovations in emergency treatment options. Recent advancements in intranasal formulations have notably transformed the market landscape. New therapies that offer rapid, non-invasive administration are becoming increasingly popular, especially in home care settings where accessibility is paramount for patients and their caregivers. The ease of use and quick action of these intranasal therapies have accelerated their adoption, allowing for immediate intervention without professional medical supervision.

Acute repetitive seizures, also referred to as seizure clusters, occur when a series of seizures transpire within a short period, typically 24 to 48 hours. These episodes can escalate into status epilepticus, a potentially life-threatening condition. For many individuals living with epilepsy, especially those who struggle to control their seizures, addressing ARS is critical. This growing need for effective treatment options is driving the market forward.

In terms of product classification, the market includes a range of solutions, each addressing the specific needs of patients. One of the leading segments is characterized by its user-friendly and non-invasive delivery method, which facilitates quick absorption and rapid seizure control-an essential factor during emergencies. The approval of certain treatments by regulatory bodies has further enhanced their acceptance and use within the healthcare community. When considering distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online platforms.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$2.7 Billion
Forecast Value	$7.7 Billion
CAGR	12.4%

Hospital pharmacies are anticipated to see significant growth, with a projected CAGR of 12.2%. This increase is driven by the frequent hospital admissions related to acute repetitive seizures, leading to heightened demand for effective seizure management medications. Additionally, these pharmacies often work closely with specialists to create effective protocols for seizure treatment, thus improving both the accessibility and efficacy of the medications. North America acute repetitive seizures market reached USD 1.1 billion in 2023 and is expected to grow at an impressive CAGR of 12.3%.

The region's high prevalence of epilepsy significantly influences the demand for effective treatment options, while a well-established healthcare system supports timely diagnoses and interventions. Moreover, increased public awareness and education surrounding seizure disorders have resulted in more frequent diagnoses, further driving market growth. Overall, the acute repetitive seizures market is poised for significant advancements as the need for effective, accessible treatment options continues to rise.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of epilepsy and seizure disorders
  - 3.2.1.2 Development of novel rescue medications
  - 3.2.1.3 Advances in non-invasive drug delivery systems
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Limited awareness and diagnosis
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 USL-261
5.3 Diastat Rectal Gel (DRG)
5.4 NRL-1
5.5 Other products

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Intranasal
6.3 Rectal
6.4 Oral
6.5 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE